Literature DB >> 29463462

Vasoactive Inotropic Score as a Predictor of Mortality in Adult Patients With Cardiogenic Shock: Medical Therapy Versus ECMO.

Soo Jin Na1, Chi Ryang Chung1, Yang Hyun Cho2, Kyeongman Jeon3, Gee Young Suh3, Joong Hyun Ahn4, Keumhee C Carriere5, Taek Kyu Park6, Ga Yeon Lee6, Joo Myung Lee6, Young Bin Song6, Joo-Yong Hahn6, Jin-Ho Choi6, Seung-Hyuk Choi6, Hyeon-Cheol Gwon6, Jeong Hoon Yang7.   

Abstract

INTRODUCTION AND
OBJECTIVES: This study investigated whether the vasoactive inotropic score (VIS) is independently predictive of mortality in cardiogenic shock (CS).
METHODS: This study was retrospective, observational study. Patients who were admitted to the cardiac intensive care unit from January 2012 to December 2015 were screened, and 493 CS patients were finally enrolled. To quantify pharmacologic support, the patients were divided into 5 groups based on a quintile of VIS: 1 to 10, 11 to 20, 21 to 38, 39 to 85, and > 85. The primary outcome was in-hospital mortality.
RESULTS: In-hospital mortalities in the 5 VIS groups in increasing order were 8.2%, 14.1%, 21.1%, 32.0%, and 65.7%, respectively (P < .001). Multivariable analysis indicated that VIS ranges of 39 to 85 (aOR, 3.85; 95%CI, 1.60-9.22; P = .003) and over 85 (aOR, 10.83; 95%CI, 4.43-26.43; P < .001) remained significant prognostic predictors for in-hospital mortality. With multiple logistic regression to remove any confounding effects, we found that the localized regression lines regarding the odds of death intersected each other's (medical therapy alone and combined extracorporeal membrane oxygenation group) path at VIS = 130. In contrast to linear correlation between VIS and mortality for patients treated with medical therapy alone, there was little association between a VIS of 130 or more and the probability of in-hospital mortality for patients who were treated with extracorporeal membrane oxygenation.
CONCLUSIONS: A high level of vasoactive inotropic support during the first 48hours was significantly associated with increased in-hospital mortality in adult CS patients.
Copyright © 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cardiogenic shock; Escala de inotrópicos vasoactivos; Extracorporeal membrane oxygenation; Oxigenador extracorpóreo de membrana; Shock cardiogénico; Vasoactive inotrope score

Mesh:

Substances:

Year:  2018        PMID: 29463462     DOI: 10.1016/j.rec.2018.01.003

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  12 in total

1.  Percutaneous Left Ventricular Assist Device in Cardiogenic Shock: A Five-Year Single Canadian Center Initial Experience.

Authors:  Cvetan Trpkov; Jordan D Gibson; Robert J H Miller; Andrew D M Grant; Gregory Schnell; Bryan J Har; Brian Clarke
Journal:  CJC Open       Date:  2020-05-18

2.  Escalation and de-escalation of mechanical circulatory support in cardiogenic shock.

Authors:  Letizia F Bertoldi; Clement Delmas; Patrick Hunziker; Federico Pappalardo
Journal:  Eur Heart J Suppl       Date:  2021-03-27       Impact factor: 1.803

3.  Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock.

Authors:  Richard G Jung; Pietro Di Santo; Rebecca Mathew; Omar Abdel-Razek; Simon Parlow; Trevor Simard; Jeffrey A Marbach; Taylor Gillmore; Brennan Mao; Jordan Bernick; Pascal Theriault-Lauzier; Angel Fu; Lawrence Lau; Pouya Motazedian; Juan J Russo; Marino Labinaz; Benjamin Hibbert
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

4.  Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism.

Authors:  Bui Hai Hoang; Phuc Giang Do; Lac Duy Le; Thao Thi Huong Bui; Thinh Nghia Bui; Quan Minh Nguyen; Duong Hoang To; Anh Dat Nguyen; Michael M Dinh; Samuel Z Goldhaber; Richard Day; Hieu Lan Nguyen
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

5.  Predictors of In-hospital Mortality in Cardiogenic Shock Patients on Vasoactive or Inotropic Support.

Authors:  Shuktika Nandkeolyar; Tanya Doctorian; Gary Fraser; Rachel Ryu; Colleen Fearon; David Tryon; Whitney Kagabo; Dmitry Abramov; Christopher Hauschild; Liset Stoletniy; Anthony Hilliard; Antoine Sakr
Journal:  Clin Med Insights Cardiol       Date:  2021-10-27

6.  Validation of the vasoactive-inotropic score in predicting pediatric septic shock mortality: A retrospective cohort study.

Authors:  Antonius Hocky Pudjiadi; Dwi Lestari Pramesti; Sudung O Pardede; Mulyadi M Djer; Rinawati Rohsiswatmo; Nastiti Kaswandani
Journal:  Int J Crit Illn Inj Sci       Date:  2021-09-25

7.  Relationship between Clinical Outcomes and Cardiopulmonary Resuscitation Time in Patients with Acute Myocardial Infarction Treated by Extracorporeal Membrane Oxygenation-Assisted Primary Percutaneous Coronary Intervention.

Authors:  Sungsoo Cho; Wonkyung Lee; Seong Hoon Lim; Tae Soo Kang
Journal:  Korean Circ J       Date:  2018-08       Impact factor: 3.243

8.  Early use of hemoadsorption in patients after out-of hospital cardiac arrest - a matched pair analysis.

Authors:  Muharrem Akin; Vera Garcheva; Jan-Thorben Sieweke; Ulrike Flierl; Hannah C Daum; Johann Bauersachs; Andreas Schäfer
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

9.  Clinical Significance of Low-Flow Time in Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation: Results from the RESCUE Registry.

Authors:  Ik Hyun Park; Jeong Hoon Yang; Woo Jin Jang; Woo Jung Chun; Ju Hyeon Oh; Yong Hwan Park; Cheol Woong Yu; Hyun-Joong Kim; Bum Sung Kim; Jin-Ok Jeong; Hyun Jong Lee; Hyeon-Cheol Gwon
Journal:  J Clin Med       Date:  2020-11-07       Impact factor: 4.241

10.  Optimal Mean Arterial Pressure for Favorable Neurological Outcomes in Survivors after Extracorporeal Cardiopulmonary Resuscitation.

Authors:  Yun Im Lee; Ryoung-Eun Ko; Jeong Hoon Yang; Yang Hyun Cho; Joonghyun Ahn; Jeong-Am Ryu
Journal:  J Clin Med       Date:  2022-01-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.